BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23161489)

  • 21. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency.
    Blackburn JS; Liu S; Raiser DM; Martinez SA; Feng H; Meeker ND; Gentry J; Neuberg D; Look AT; Ramaswamy S; Bernards A; Trede NS; Langenau DM
    Leukemia; 2012 Sep; 26(9):2069-78. PubMed ID: 22538478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.
    Gekas C; D'Altri T; Aligué R; González J; Espinosa L; Bigas A
    Leukemia; 2016 Oct; 30(10):2002-2010. PubMed ID: 27125305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
    Piya S; Yang Y; Bhattacharya S; Sharma P; Ma H; Mu H; He H; Ruvolo V; Baran N; Davis RE; Jain AK; Konopleava M; Kantarjian H; Andreeff M; You MJ; Borthakur G
    Leukemia; 2022 May; 36(5):1261-1273. PubMed ID: 35173274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
    Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
    J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
    Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
    Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
    Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
    PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoallelic
    Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
    Front Immunol; 2022; 13():867443. PubMed ID: 35401501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
    Palomero T; Ferrando A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.
    Ortega M; Bhatnagar H; Lin AP; Wang L; Aster JC; Sill H; Aguiar RC
    Leukemia; 2015 Apr; 29(4):968-76. PubMed ID: 25311243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Notch in Leukemia.
    McCarter AC; Wang Q; Chiang M
    Adv Exp Med Biol; 2018; 1066():355-394. PubMed ID: 30030836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells.
    Riz I; Hawley TS; Luu TV; Lee NH; Hawley RG
    Mol Cancer; 2010 Jul; 9():181. PubMed ID: 20618946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
    Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
    Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch dimerization is required for leukemogenesis and T-cell development.
    Liu H; Chi AW; Arnett KL; Chiang MY; Xu L; Shestova O; Wang H; Li YM; Bhandoola A; Aster JC; Blacklow SC; Pear WS
    Genes Dev; 2010 Nov; 24(21):2395-407. PubMed ID: 20935071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.